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Objective: Phantom bite syndrome (PBS) is characterized by a persistent uncomfortable sensation of occlusion
without an evident occlusal discrepancy. The aims of this retrospective cross-sectional study were to assess psy-
chiatric comorbidities and evaluate psychopharmacological outcomes of PBS.
Methods: The database of the Psychosomatic Dentistry Clinic of TokyoMedical and Dental University Dental Hos-
pital was reviewed for cases of PBS diagnosed between April 2009 and March 2012. Clinical Global Impression
indices were used to assess psychopharmacological outcomes.
Results: The review revealed 130 patients (107women, 23men)with a mean age of 53.0±13.1 years. They pre-
viously visited 4.4±3.4 dental clinicsand had amean symptomduration of 5.3±5.4 years. Only 24 (18.5%) of 63
(48.5%) patients with psychiatric comorbidities had schizophrenia, major depressive disorder, or bipolar disor-
der. The frequency of psychiatric comorbidities was signiﬁcantly lower in PBS with a dental trigger than that
without a speciﬁc trigger. Moreover, patients without a psychiatric comorbidity showed signiﬁcantly better out-
comes than those with a psychiatric comorbidity. Forty patients (30.8%) showed remarkable clinical improve-
ment after receiving amitriptyline, mirtazapine, or aripiprazole.
Conclusion: PBS is generally not associated with severe psychiatric disorders. Absence of a dental trigger predicts
a psychiatric comorbidity, which affects the psychopharmacological outcome. Antidepressant or antipsychotic
therapy may be effective for symptommanagement in PBS.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Phantom bite syndrome (PBS) [1] also termed occlusal discomfort
[2], or occlusal dysesthesia [3,4], is characterized by a persistent
uncomfortable sensation of occlusions without an evident occlusal
discrepancy. Affected individuals complain that their occlusion is
“wrong,” “somewhat high/low,” or “the bite is off.” They nomadically
visit various dentists seeking “bite correction” because of their strong
belief in dental treatment despite possible symptom exacerbation [1].
PBS has been regarded as a psychiatric disorder [1,5–11]related to para-
noia, personality disorder, or somatoform disorder, while some authors
have suggested proprioceptive dysfunction, false peripheral feed-back
[12], or phantom occlusal sensation in the central nervous system
[13–17] as possible etiologies. However, little is known about its psychi-
atric comorbidities [10,18]. Themanagement of PBS includes referral fortic Dentistry, Graduate School of
l University, 1-5-45 Yushima,
.
. This is an open access article underpsychological evaluation [1,5,6] and avoiding occlusal adjustment [3,11,
12]. Antipsychotic drugs [1,3,6,11,12] and antidepressants [19–25] have
been reported to be effective, but pharmacological evidence from clini-
cal studies is lacking.
The aims of this retrospective cross-sectional study were to assess
psychiatric comorbidities and evaluate psychopharmacological out-
comes of PBS.Methods
Subjects
We reviewed the database of the Psychosomatic Dentistry Clinic of
Tokyo Medical and Dental University Dental Hospital, Tokyo, Japan, for
all patients diagnosed with PBS between April 2009 and March 2012.
The Psychosomatic Dentistry Clinic specializes in the management of
various oral psychosomatic disorders such as burningmouth syndrome,
atypical odontalgia (atypical facial pain), disturbance in taste or saliva-
tion, and PBS.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Differences in the frequencies of psychiatric comorbidities between patients with
PBS triggered by dental treatment and thosewithout a speciﬁc trigger at onset. Psychiatric
comorbidities were signiﬁcantly less frequent in the patients with PBS appearing after
dental treatment.
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Medical and Dental University (no. 356). All subjects provided written
informed consent for participation.
Before diagnosis, the patients were interviewed to obtain detailed
information on symptoms and dental treatments including occlusal
adjustment. Thorough clinical examinations were performed by at
least three dentists, including prosthodontic andorthodontic specialists,
to exclude occlusal discrepancies and temporomandibular joint disor-
ders. Previously reported clinical characteristics and criteria were also
considered for deﬁnitive diagnosis [12,26],
Amitriptyline was prescribed as the ﬁrst choice for psychopharma-
cological management based previous reports [19–25]. Other antide-
pressants or antipsychotic drugs were added or switched consensually
according to weekly clinical assessments of symptom severity, quality
of life, and adverse reactions.
Assessments
Clinicodemographic data and information on triggers and oral
psychosomatic comorbidities were obtained from medical charts.
Psychiatric diagnoseswere recorded from referral letters of the patients’
psychiatrists.
Psychopharmacological outcomes were assessed consensually by
experienced attending doctors using the Global Improvement and Efﬁ-
cacy Index of the Clinical GlobalImpression (CGI) scale [27] 6 months
after the initial examination. CGI scores representing “very much
improved” and “much improved”were considered indicative of clinical
improvement. “Improved” implied a therapeutic response, but insufﬁ-
cient recovery.
Statistical analysis
Datawere analyzes by two-tailed t-test, chi-square test, and binomial
logistic regression using PASW Statistics for Windows version 17Table 1
Clinicodemographic data of the patients with PBS.
Parameter Cases (N=130)
Gender (women/men) 107/23
Age (years) 53.0 ±13.1
Duration of illness (years) 5.3 ±5.4
Number of previously visited dental clinics 4.4 ±3.4
Triggers
Absent 30 (23.1)
Dental treatment 96 (73.8)
Prosthodontic 57 (43.8)
Occlusal adjustment 14 (10.8)
Orthodontic 11 (8.5)
Dental implant placement 9 (6.9)
Extraction 5 (3.4)
Others 4 (3.1)
Oral psychosomatic comorbidities
Absent 86 (66.2)
Presenta 44 (33.8)
Burning mouth syndrome 19
Atypical odontalgia (atypical facial pain) 29
Disturbance in taste or salivation 12
Psychiatric comorbidities
Absent 67 (51.5)
Presenta 63 (48.5)
Major depressive disorder 17
Unspeciﬁc depressive disorder 10
Bipolar disorder 3
Anxiety disorder 10
Somatic symptom disorder 15
Schizophrenia 4
Personality disorder 1
Others 5
Values represent mean ± SD or n (%).
a Includes multiple diagnoses.(SPSS, Inc., Chicago, IL). For binomial logistic regression, the dependent
variable was psychopharmacological outcome (improved =1, not im-
proved=0), while the independent variables were number of previous-
ly visited clinics, presence of a dental trigger, presence of an oral
psychosomatic comorbidity, and presence of a psychiatric comorbidity.
P b0.05 was considered signiﬁcant. Results are expressed as mean ±
standard deviation (SD) or number of patients (%).Results
Patient characteristics
The review revealed 130 patients with PBS among 1629 outpatients including 107
women (82.3%) and 23men ( 17.7%). Themean agewas 53.0±13.1 years.Women tended
to be older than men without a signiﬁcant difference (53.7 ±13.0 vs. 47.6 ±13.5 years;
P =0.058). The mean symptom duration was 5.3 ±5.4 years, and 80 patients (61.5%)
suffered from PBS for under 5 years (Table 1).
Thirty patients (23.1%) did not have speciﬁc triggers at onset, but 96 patients (73.8%)
developed symptoms after various dental treatments. Four patients reported trafﬁc acci-
dents and abdominal or ocular surgeries as triggers.
In addition, 44 patients (33.8%) complained of other oral psychosomatic disorders.
Some met the diagnostic criteria for two oral psychosomatic disorders.
Psychiatric comorbidities were present in 63 patients (48.5%), including two cases of
eating disorders, two cases of adjustment disorder, and one case of substance-related dis-
order. Of the 17 patients with major depressive disorder, 12 patients were in remission at
the onset of PBS.
As shown in Fig. 1, 40.6% (39/96) of the patients with dental triggers and 70.0%
(21/30) of those without speciﬁc triggers had psychiatric comorbidities (P b0.001).
Table 2 shows the characteristic clinical symptoms and their frequencies.
Themost common complaints concerned altered occlusal height (83.8%) and uncom-
fortable occlusal sensation (94.6%) including chewing difﬁculty and sliding of the jaw or
teeth while biting. Moreover, 114 patients (87.7%) suffered from medically unexplained
somatoform symptoms: bad posture, shoulder stiffness, headache, and malaise. PBS dis-
turbed quality of lives in 122 patients (86.2%). Because general dental treatments did
not improve the symptoms, 104 patients (80.0%) visited several dental clinics (4.4 ±3.4
clinics), ranging from fewer than ﬁve clinics (95 patients) to 26 clinics (one patient).Table 2
Frequency of common symptoms of PBS.
Symptom Cases
1 Uncomfortable occluding position, difﬁculty in chewing,
sliding sensation of the jaw or teeth
123 (94.6)
2 No particular occlusal abnormality 119 (91.5)
3 Medically unexplained symptom in their other body parts 114 (87.7)
4 Disturbed quality of life 112 (86.2)
5 Sensation of altered occlusal height 109 (83.8)
6 Visits to several dental clinics 104 (80.0)
7 PBS appearing soon after dental treatment 96 (73.8)
Values represent n (%).
Multiple answers were counted.
Table 3
Comparison of CGI categories according to the triggers of PBS and presence of psychiatric
comorbidities.
Triggers Psychiatric
comorbidity
Caregory Total
(N=130)
Dental treatment
(n=96)
Absent
(n=30)
Present
(n=63)
Absent
(n=67)
Very much
improved
20 (15.4) 14 (14.6) 6 (20.0) 6 (9.5) 14 (20.9)
Much improved 20 (15.4) 14 (14.6) 6 (20.0) 7 (11.1) 13 (19.4)
Improved 18 (13.8) 12 (12.5) 5 (16.7) 11 (17.5) 7 (10.4)
No changed 19 (14.6) 12 (12.5) 7 (23.3) 10 (15.9) 9 (13.4)
Worse 1 (0.8) 1 (1.0) 0 (0) 1 (1.6) 0 (0)
Much worse 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Very much worse 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
None assessed 52 (40.0) 43 (44.8) 6 (20.0) 28 (44.4) 24 (35.8)
Dropped out 19 (14.6) 15 (15.6) 3 (10.0) 11 (17.5) 8 (11.9)
Refused
treatment
17 (13.1) 15 (15.6) 1 (3.3) 7 (11.1) 10 (14.9)
Only follow-up 8 (6.2) 7 (7.3) 1 (3.3) 4 (6.3) 4 (6.0)
Psychiatric
referral
6 (4.6) 4 (4.2) 1 (3.3) 4 (6.3) 2 (3.0)
Others 2 (1.5) 2 (2.1) 0 (0) 2 (3.2) 0 (0)
Values represent n (%).
Table 4
Factors affecting the psychopharmacological outcome.
Factor P Exp(B) 95% conﬁdence
interval
Lower Upper
Number of previously visited dental clinics 0.070 1.158 0.988 1.358
Triggers 0.853 1.108 0.374 3.282
Oral psychosomatic comorbidities 0.081 0.405 0.147 1.119
Psychiatric comorbidities 0.014⁎ 3.723 1.302 10.647
⁎ P b0.05
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Psychopharmacological outcomes of 78 patients (60.0%) were assessed, of whom 40
patients (51.3%) showed clinical improvement (Table 3). Fifty two cases (40.0%) could
not be assessed because of no contact after prescription of antidepressants, refusal of psy-
chopharmacological treatment due to a strong conviction that occlusal adjustment was
needed, requests of consultations for dental treatments, or psychiatric referrals (a patient
with schizophrenia, two patientswith eating disorders, and three patients requesting gen-
eral dental examination by their psychiatrists).
Concerning triggers, clinical improvement was more common in the patients with
dental triggers than in those without speciﬁc triggers, although the difference was not
signiﬁcant (P=0.819). Further, signiﬁcantlymore patients without psychiatric comorbid-
ities showed clinical improvement than those with psychiatric comorbidities (P=0.025).
Presence of a psychiatric comorbidity signiﬁcantly affected the psychopharmacological
outcome (odds ratio =3.620; Table 4).Table 5
Summary of the psychopharmacological treatments.
TCA SSRI
Parameter Amitriptyline
(n =29)
Paroxetine
(n =3)
Sertraline
(n =9)
Fluv
(n =
Mean duration of administration until
clinical improvement (days)
74.9 ±56.9 NA 79.3 ±53.8 23
Mean effective dose for clinical
improvement (mg)
21.9 ±8.6 NA 27.0 ±10.8 18
Very much improved 4 0 3 1
Much improved 6 0 3 1
Improved 3 1 1 0
No change 12 2 2 2
Discontinued 4 0 0 0
TCA: tricyclic antidepressants; SSRI: serotonin selective reuptake inhibitors; SNRI: serotonin an
depressants; DPA: dopamine partial agonist; NA: not applicable
Multiple answers were counted.Sixty-six of the 78 patients who underwent psychopharmacological treatment were
prescribed medication at our clinic, while others were followed up with prescriptions
from other clinics. Therefore, the efﬁcacy of medications was assessed only in the 66 pa-
tients who received prescriptions at our clinic. The most prescribed medication was ami-
triptyline (29 cases). With amitriptyline, four and six cases were scored as “very much
improved”and “much improved,” respectively (Table 5). Until clinical improvement, the
mean duration of administration and dose were 74.9 ±56.9 days and 21.9 ±8.6 mg,
respectively. With mirtazapine, also frequently prescribed, two patients had “very much
improved” and six patients had “much improved.” Its mean duration of administration
was 64.6±58.5 days, and themean dosewas 12.6±9.2mg. Themost prescribed antipsy-
chotic drug was aripiprazole (27 cases). The psychopharmacological outcome with
aripiprazole included “very much improved” in four patients and “much improved” in
four other patients. The mean duration of administration was 59.0 ±37.4 days and
mean dose was 1.3 ±0.4 mg.
Table 6 shows the adverse reactions of each medication. The most common com-
plaints were drowsiness and constipation with amitriptyline (12 and seven cases, respec-
tively) and mirtazapine (six and three cases, respectively). Patients complained of fatigue
(three cases), drowsiness (two cases), irritation (two cases), and nausea (two cases)while
taking aripiprazole. Adherence was 86.2% (25/29), 90.5% (19/21), and 77.8% (21/27) dur-
ing administration of amitriptyline, mirtazapine, and aripiprazole, respectively.Discussion
This large retrospective survey of PBS revealed three principal ﬁnd-
ings. First, most patients with PBS did not have severe psychiatric disor-
ders, and PBS following dental triggers was associatedwith signiﬁcantly
low incidence of psychiatric comorbidities. Second, presence of psychi-
atric comorbidity affected the psychopharmacological outcome. Third,
about 30% of the patients showed remarkable clinical improvement
during antidepressant or antipsychotic therapy without sever adverse
reactions.
We found that PBS occurs predominantly in women and adults aged
30−70 years, with a peak in the 50s and 60s, supporting previous
results [4].
The common symptoms included discomfort and difﬁculty with
mastication, sliding of the jaw or teethwhile chewing, and altered occlu-
sal height. Many patients visited several dental clinics seeking occlusal
adjustment, and the number of patients refusingpsychopharmacological
treatment was remarkably high, especially among those with dental
triggers. These results reﬂect the fact that patientswith PBS often request
repeated occlusal adjustment because they strongly believe that they
have an occlusal discrepancy. However, general dental treatment can
hardly cure PBS. Therefore, dentists should not feel compelled to provide
incorrect treatment, which could worsen symptoms. Instead, they
should explain the necessity of comprehensive management of PBS.
We noted that 48.5% (63/130) of the patients had psychiatric comor-
bidities, including 18.5% (24/130)with schizophrenia, major depressive
disorder, or bipolar disorder. Contrarily, previous studies [10,18] have
shown that 66−84% of the patients with PBS have a psychiatric history.
Although screening for psychiatric disorders is important, all
patients with PBS would not see psychiatrists. Further, they would notSNRI NaSSA DPA
oxamine
4)
Escitalopram
(n =4)
Milnacipran
(n =7)
Duloxetine
(n =7)
Mirtazapine
(n =21)
Aripiprazole
(n =27)
.5 ±3.5 17.5 ±21.7 152.3 ±92.7 28.0 64.6 ±58.5 59.0 ±37.4
.8 ±8.8 5.6 ±5.3 50.6 ±22.0 20.0 12.6 ±9.2 1.3 ±0.4
2 2 1 2 4
1 2 0 6 4
0 0 2 1 2
0 3 4 10 11
1 0 0 2 6
d noradrenaline reuptake inhibitors; NaSSA: noradrenergic and speciﬁc serotonergic anti-
Table 6
Adverse reactions.
TCA SSRI SNRI NaSSA DPA
Rzeaction Amitriptyline
(n =29)
Paroxetine
(n =3)
Sertraline
(n =9)
Fluvoxamine
(n =4)
Escitalopram
(n =4)
Milnacipran
(n =7)
Duloxetine
(n =7)
Mirtazapine
(n =21)
Aripiprazole
(n =27)
Drowsiness 12 1 1 3 1 2 2 6 2
Constipation 7 0 2 0 0 2 2 3 1
Weight gain 3 0 0 0 0 0 0 1 1
Nausea 1 0 2 0 0 1 2 2 3
Diarrhea 0 0 0 0 0 0 0 0 1
Dysuria 0 0 0 0 0 1 0 0 0
Pollakiuria 0 0 0 0 0 1 0 0 1
Edema 0 0 1 0 0 0 0 0 0
Staggering 1 0 0 0 1 1 0 1 1
Dizziness 0 0 0 0 0 1 0 0 1
Dry mouth 3 0 1 0 0 0 0 0 0
Decreased appetite 0 0 1 0 1 0 1 0 0
Malaise 1 0 0 0 1 1 0 0 3
Irritation 0 0 0 0 0 0 0 0 2
Headache 0 0 0 0 0 0 0 0 1
Sleep disorders 0 0 0 0 0 0 0 0 1
Nightmares 0 0 0 0 0 0 0 1 0
TCA: tricyclic antidepressants; SSRI: serotonin selective reuptake inhibitors; SNRI: serotonin and noradrenaline reuptake inhibitors; NaSSA: noradrenergic and speciﬁc serotonergic anti-
depressants; DPA: dopamine partial agonist
Multiple answers were counted.
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atric symptoms and generally complain about occlusion [24]. Interest-
ingly, presence of a dental trigger at PBS onset is associated with
lower incidence of psychiatric comorbidities. Therefore, absence of a
dental trigger might predict a psychiatric comorbidity.
Clinical improvement occurred in 30.8% (40/130) of all the patients,
especially in those with PBS after a dental trigger and those without a
psychiatric comorbidity. These results suggest that psychopharmaco-
logical treatments are more effective in patients with PBS appearing
after dental treatment and having no psychiatric history. The ﬁnding
of poor outcomes in patients with psychiatric comorbidities is consis-
tent with a previous report [28].
Previous reports describe cases in which amitriptyline [20–24],
milnacipran [19] and duloxetine [25] were effective, but little is
known about aripiprazole [21], and mirtazapine. We found that
aripiprazole and mirtazapine may be as effective as amitriptyline for
PBS. However, detailed clinical studies are warranted.
The underlyingmechanisms of PBS have not been deﬁned, but some
theories have been proposed.
Leon-Salazar et al. [15] suggested that PBSmay result from neural re-
organization induced by a noxious stimulus, such as a dental treatment.
Despite change or loss of occlusal input, cerebral regions involved in oc-
clusal proprioception may remain unchanged and retain their function.
In addition, Alberts [17] and Melzack et al. [16] indicated that a change
in the somatotopic map may result in phantom sensations. Moreover,
asymmetrical regional cerebral blood ﬂow may result in PBS [21]. Brain
imaging studies are necessary to clarify the pathophysiology of PBS.
This study has some limitations. First, the patient’s psychiatrists di-
agnosed the psychiatric disorders; only referral information was used
to classify these comorbidities. Second, the duration of drug administra-
tionwas not consistent. Prospective investigations of psychopharmaco-
logical efﬁcacy with equal durations and doses are required.
In conclusion,most patients with PBS do not have severe psychiatric
comorbidities. Absence of a dental trigger of PBS may predict a psychi-
atric comorbidity, which affects the psychopharmacological outcome.
Antidepressants or antipsychotic therapy may be beneﬁcial for symp-
tom management in PBS.
Conﬂict of Interests Statement
This study was supported in part by a Grant-in-aid for Science
Research from the Japan Society for the Promotion of science(No. 24593141). The authors have no competing interests to report in
this study.Acknowledgments
This study was supported in by a Grant-in-aid for Science Research
from the Japan Society for the Promotion of Science (No. 24593141).
The authors have no competing interests to report.References
[1] Marbach JJ. Phantom bite. Am J Orthod 1976;70:190–9.
[2] Harris M, Feinmann C, Wise M, Treasure F. Temporomandibular joint and orofacial
pain: clinical and medicolegal management problems. Br Dent J 1993;174:129–36.
[3] Clark GT, Tsukiyama Y, Baba K, Simmons M. The validity and utility of disease detec-
tion methods and of occlusal therapy for temporomandibular disorders. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod 1997;83:101–6.
[4] Hara ES, Matsuka Y, Minakuchi H, Clark GT, Kuboki T. Occlusal dysesthesia: a quali-
tative systematic review of the epidemiology, aetiology and management. J Oral
Rehabil 2012;39:630–8.
[5] Marbach JJ. Phantom bite syndrome. Am J Psychiatry 1978;135:476–9.
[6] Marbach JJ, Varoscak JR, Blank RT, Lund P. "Phantom bite": classiﬁcation and treat-
ment. J Prosthet Dent 1983;49:556–9.
[7] Shetti S, Chougule S. Phantom Bite - A Case Report of a Rare Entity. J Dental Allied Sci
2012;1:82–4.
[8] Tsukiyama Y, Yamada A, Kuwatsuru R, Koyano K. Bio-psycho-social assessment of
occlusal dysaesthesia patients. J Oral Rehabil 2012;39:623–9.
[9] Koga C, Kitajima S, Nakamura C, Aoki M, Kameyama T, Tomita W, et al. A case of
phantom bite. Japan J Psychosom Dent 2001;16:95–7 (in Japanese).
[10] Tamaki K. The Present Condition, our View and Treatment Approach of Patients with
Uncomfortable Occlusion in Dentistry. Japan J Psychosom Dent 2009;49:1079–84
(in Japanese).
[11] Jagger RG, Korszun A. Phantom bite revisited. Br Dent J 2004;197:241–3.
[12] Clark G, Simmons M. Occlusal dysesthesia and temporomandibular disorders: is
there a link? Alpha Omegan 2003;96:33–9.
[13] Marbach JJ. Orofacial phantom pain: theory and phenomenology. J Am Dent Assoc
1996;127:221–9.
[14] Davis KD, Kiss ZH, Luo L, Tasker RR, Lozano AM, Dostrovsky JO. Phantom sensations
generated by thalamic microstimulation. Nature 1998;391:385–7.
[15] Leon-Salazar V, Morrow L, Schiffman EL. Pain and persistent occlusal awareness:
what should dentists do? J Am Dent Assoc 2012;143:989–91.
[16] Melzack R, Coderre TJ, Katz J, Vaccarino AL. Central neuroplasticity and pathological
pain. Ann N Y Acad Sci 2001;933:157–74.
[17] Alberts IL. Idiopathic orofacial pain: A review. Internet J Pain Symptom Control
Palliat Care 2009;6.
[18] Miyachi H,Wake H, Tamaki K, Mitsuhashi A, Ikeda T, Inoue K, et al. Detecting mental
disorders in dental patients with occlusion-related problems. Psychiatry Clin
Neurosci 2007;61:313–9.
[19] Toyofuku A, Kikuta T. Treatment of phantom bite syndrome with milnacipran - a
case series. Neuropsychiatr Dis Treat 2006;2:387–90.
259M. Watanabe et al. / Journal of Psychosomatic Research 78 (2015) 255–259[20] Umezaki Y, Sato Y, Katagiri A,WatanabeM, Takenoshita M, Yoshikawa T, et al. A case
of "Phantom Bite Syndrome" ameliorated by the administration of amitriptyline.
Japan J Psychosom Dent 2012;27:44–9 (in Japanese).
[21] Umezaki Y, Watanabe M, Takenoshita M, Yoshikawa T, Sakuma T, Sako E, et al. A
case of phantom bite syndrome ameliorated with the attenuation of the asymmet-
rical pattern of regional cerebral blood ﬂow. Japan J Psychosom Dent 2013;28:
30–4 (in Japanese).
[22] Toyofuku A, Kikuta T, Gotoh T, Koga T, Shimamura T, Miyako H. A case report: Treat-
ment of TMJ arthrosis complaininf of systemic disorder with "description of impres-
sions". Japan J Psychosom Dent 1994;9:192–9 (in Japanese).
[23] Toyofuku A, Yoshida M, Shimomura T, Koga T, Seto T, Shimizu T, et al. Treatment of
TMJ disorder with Serious Psychosomatic Complains under Hospitalization. Japan J
Psychosom Dent 1996;11:88–95 (in Japanese).[24] Toyofuku A, Yoshida M, Shimizu T, Naitou Y, Kikuta T, Miyako H. The Efﬁcacy of
Distinguishing between the Patient's Occlusion and Character Traits in the Treat-
ment of a Case of TMJ disorder. Japan J PsychosomDent 1998;13:51–8 (in Japanese).
[25] Bhatia NK, Bhatia MS, Bhatia NK, Singh HP. Occlusal dysethesia responded to
Duloxetine. Delhi Psychiatry J 2013;16:453–4.
[26] Tamaki K, Inagaki S, Ogawa T, Oguchi H, Kato T, Suganuma T, et al. Occlusal discom-
fort syndrome. Annu Jpn Prosthodont Soc 2013;5:369–86 (in Japanese).
[27] Rating scales and assessment instruments for use in pediatric psychopharmacology
research. Psychopharmacol Bull 1985;21:714–1124.
[28] Watanabe M, Katagiri A, Umezaki Y, Sakuma T, Sako E, Yoshikawa T, et al. Clinico-
statistical Study on 1210 outpatients examined at the department of Psychosomatic
Dentistry. Japan J Psychosom Dent 2012;27:37–43 (in Japanese).
